Life Sciences

  • October 22, 2026

    Full 9th Circ. Won't Review Surgical Robot Antitrust Fight

    The full Ninth Circuit declined to reconsider an appellate panel's recent decision reviving a surgical repair company's antitrust suit alleging Intuitive Surgical blocked third parties from supplying parts for its popular da Vinci surgery robot, according to an order issued Thursday.

  • October 22, 2026

    J&J Says Justices' Denial Backs Tossing Fee Suit At 3rd Circ.

    Johnson & Johnson told the Third Circuit Thursday that the U.S. Supreme Court's recent decision not to take up a group of executives' federal benefits dispute backed its position in an appeal from J&J workers who alleged their health plans were saddled with excessive prescription drug fees.

  • October 22, 2026

    Mylan Settles Connecticut's EpiPen Price Claims For $8M

    Mylan Pharmaceuticals has struck another deal to resolve claims that it illegally inflated prices for EpiPens, this time settling Connecticut state enforcers' allegations of antitrust and consumer protection law violations for $8 million.

  • October 22, 2026

    Purdue Trusts Say Sackler Bid Again Destabilizes Ch. 11 Plan

    The Purdue Pharma bankruptcy trust and trustees for some members of the Sackler family have filed separate documents in a New York bankruptcy court challenging moves they described as continued attempts by Richard S. Sackler and his wife, Lin Gao, to block parts of the drugmaker's bankruptcy plan.

  • October 22, 2026

    10x Genomics Ends Patent Fight Against Parse In Delaware

    10x Genomics has told a Delaware federal judge it will no longer pursue a patent case against Parse Biosciences Inc. over methods of analyzing genetic information, a move following the Federal Circuit's refusal to revive the remaining three patents-at-issue.

  • October 22, 2026

    FTC Wants More Info On Curium's $8B Deal For Lantheus

    The Federal Trade Commission has requested additional information about Curium's planned $8 billion acquisition of fellow radiopharmaceutical company Lantheus Holdings Inc., extending a waiting period that prevents the transaction from closing.

  • October 22, 2026

    Imperative Gets PTAB To Trim Inari Medical Device Claims

    The Patent Trial and Appeal Board has invalidated claims in an Inari Medical Inc. patent on valves used in surgery to prevent blood loss, handing another win to challenger Imperative Care as it fends off an infringement lawsuit in California.

  • October 22, 2026

    DLA Piper Hires Shook Hardy Product Liability Partner

    DLA Piper has hired a former Shook Hardy & Bacon LLP product liability partner in San Francisco who has decades of experience defending companies in high-stakes disputes involving hundreds of millions of dollars.

  • October 21, 2026

    7 Firms Advise EQT, Qiagen On $12.1B Take-Private Deal

    A long list of firms — including Davis Polk & Wardwell LLP, Linklaters LLP and Milbank LLP — are steering Sweden-based EQT Private Equity's $12.1 billion takeover of life sciences testing company Qiagen NV, according to a Wednesday announcement.

  • October 21, 2026

    Reckitt Benckiser Denies Firing Manager For Whistleblowing

    Reckitt Benckiser urged a New Jersey federal judge to end a former senior regulatory manager's suit alleging she was fired for raising product safety issues, arguing Tuesday she rejected a lateral transfer amid a global reorganization and unsuccessfully gambled the company would give in to her promotion and higher pay demands.

  • October 21, 2026

    Ill. Judge Questions Bid To Block 340B Drug Discount Law

    An Illinois federal judge seemed hesitant Wednesday to halt a state law barring drugmakers from trying to impose restrictions on pharmacies under contract with a federal drug pricing discount program, saying the state seems to be maximizing public health in an area the statute doesn't address.

  • October 21, 2026

    Intuitive Surgical Strikes $450M Deal In Robot Antitrust Suit

    Intuitive Surgical said in its quarterly earnings report Tuesday that it reached a $450 million settlement to resolve a hospital class action alleging it monopolized the market for servicing its da Vinci surgical robots, subject to approval by a California federal judge.

  • October 21, 2026

    Amarin Ends 'Skinny Label' Patent Case Against Hikma

    Amarin Pharma Inc. is dropping its patent suit over Hikma Pharmaceuticals USA Inc.'s generic version of a heart drug that uses a so-called skinny label, months after the U.S. Supreme Court shut the case down.

  • October 21, 2026

    Squire Patton Lands Akerman's Public Finance Co-Leader

    Squire Patton Boggs LLP announced Wednesday that it has added the co-chair of Akerman LLP's public finance group to bolster its capacity to handle public finance, healthcare finance and other matters.

  • October 21, 2026

    High Court Lets Block On Prison Gender Care Ban Stand

    The U.S. Supreme Court on Wednesday allowed federal prisons to continue to offer gender transition medical services to incarcerated people.

  • October 20, 2026

    Medical Device Co. Beats Investors' Alleged Demand Drop Suit

    A New York federal judge has dismissed a proposed shareholder class action alleging medical device maker Integer Holdings Corp. hid plummeting demand for cardiac devices and misled investors about its overall growth, concluding that the allegations do not suggest its disclosures in 2024 and 2025 were untrue or deceptive.

  • October 20, 2026

    Squires Grants 10 Patent Review Bids, Rejects 2 Others

    In his latest round of decisions, U.S. Patent and Trademark Office Director John Squires has granted 10 petitions seeking review of patents and denied two others, both on discretionary grounds.

  • October 20, 2026

    Genentech, Novartis Sue Amneal Over Bid To Sell Xolair Copy

    Genentech Inc. and Novartis Pharmaceuticals Corp. have filed a patent infringement suit in Delaware federal court, claiming Kashiv BioSciences' bid to sell a biosimilar copy of their prescription allergy drug Xolair amounts to patent infringement.

  • October 20, 2026

    Zymergen Investors Win Final OK Of $125M IPO Deal

    Investors in the now-defunct biotechnology company Zymergen received final approval of their $125 million deal ending claims that the company misled shareholders ahead of its initial public offering, while plaintiffs' attorneys also had their fee request approved. 

  • October 20, 2026

    2nd Circ. Won't Block Connecticut Drug Price Cap

    A Second Circuit panel affirmed a lower court's decision Tuesday, refusing to block Connecticut from enforcing a cap on generic and off-patent drug prices while a trade association for drug wholesalers challenges the statute.

  • October 20, 2026

    Omnicare Seeks 3rd Change To Ch. 11 Loan Ahead Of Maturity

    Pharmacy service provider Omnicare has asked a Texas bankruptcy judge for permission to make a third set of tweaks to its $110 million debtor-in-possession financing agreement, including when the loan comes due, saying the debtor won't be able to consummate its sale to spin off from parent company CVS before the current maturity date.

  • October 20, 2026

    8th Circ. Panel Doubts Investors' Medtronic Insulin Pump Suit

    The Eighth Circuit appeared skeptical Tuesday of investors' bid to revive allegations that medical device company Medtronic failed to properly communicate problems with an insulin pump device it manufactured and was ultimately recalled, with judges questioning arguments that certain interactions between the company and regulators weren't properly disclosed.

  • October 20, 2026

    Polsinelli Seeks Sanctions For 'Knowingly False' IP Suit

    Law firm Polsinelli PC has asked a Tennessee federal judge to sanction a medical device company for advancing what it says were "knowingly false and materially incomplete" positions in a suit accusing the firm of pursuing bad faith patent infringement claims on behalf of a client.

  • October 20, 2026

    CMA Seeks Views On Intersurgical's Teleflex Deal

    Britain's antitrust regulator invited comments Tuesday on whether local medical device maker Intersurgical's proposed $530 million acquisition of two businesses could harm competition in U.K. markets.

  • October 20, 2026

    Freshfields Hires Gibson Dunn Life Sciences Lawyer In DC

    Freshfields LLP has hired a former Gibson Dunn & Crutcher LLP lawyer who focuses his practice on identifying, assessing and mitigating risks associated with U.S. Food and Drug Administration oversight, the firm recently announced.

Expert Analysis

  • Series

    Juggling And Unicycling Make Me A Better Lawyer

    Author Photo

    Because I juggle (sometimes with fire) and ride the unicycle, friends and family used to joke that I should join the circus, but I pursued the practice of law instead and learned that my hobbies benefit my profession in several important ways, says Morgan Eddy at Smith Currie.

  • AI Note-Taking Suits May Fill Gap In Privacy Law Structure

    Author Photo

    A recent class action against Granola joins other pending lawsuits against AI note-taking providers, highlighting the legal uncertainty surrounding these tools, but there are practical steps companies using "invisible" AI services can take to mitigate risk, including conducting inventories and reviewing access permissions, say attorneys at Barnes & Thornburg.

  • FDA Closeout Letter Suggests Relaxing Stance On Wearables

    Author Photo

    The U.S. Food and Drug Administration's recent decision not to pursue enforcement action against Whoop's wearable blood pressure tracker, read together with guidance released earlier this year, suggests a softer shift in the FDA's approach to regulating wearables, say attorneys at Arnold & Porter.

  • Fed. Circ. Dental IP Ruling Reinforces Prior Art Framework

    Author Photo

    The Federal Circuit's recent decision in Dental Monitoring v. Align Technology reaffirms the necessity of substantive written description support for establishing an earlier effective prior art date under the America Invents Act, and aligns Patent Trial and Appeal Board practice with district court litigation, say attorneys at Morgan Lewis.

  • Justices' Hikma Reasoning May Extend Well Beyond Pharma

    Author Photo

    The active steps framework announced by the U.S. Supreme Court in its Hikma v. Amarin decision, finding that Amarin failed to plausibly allege inducement of infringement, has the potential to reshape how courts evaluate inducement claims across patent, copyright and other doctrines, say attorneys at BCLP.

  • Teva MDL Loss Shows DPAs Can Return To Haunt Civil Suits

    Author Photo

    Teva’s recent partial summary judgment loss in antitrust multidistrict litigation reinforces the importance of carefully scrutinizing any statement of facts a company admits to in a deferred prosecution agreement, and illustrates the potential costs of resolving a criminal investigation this way, say attorneys at Sheppard.

  • An Inside Look At Squires' Discretionary Denials

    Author Photo

    A deep dive into the discretionary denials issued by U.S. Patent and Trademark Office Director John Squires since he took over last year identifies trends in commonly asserted arguments and how they correlate with institution outcomes, say attorneys at Kirkland & Ellis.

  • Series

    Ballet Makes Me A Better Lawyer

    Author Photo

    A lifetime of learning and performing ballet taught me that success — whether in dance or practicing law — comes only through hours of thorough preparation, boundless energy and relentless effort, says Sharon Katz-Pearlman at Greenberg Traurig.

  • Fed. Circ. In July: Meeting The Enablement Requirement

    Author Photo

    The Federal Circuit's decision in Wyeth v. AstraZeneca last month exemplifies when a generalized conception of an invention is insufficient to enable the full scope of asserted patent infringement claims, and may lead to more enablement challenges, say attorneys at Knobbe Martens.

  • Series

    Taekwondo Makes Me A Better Lawyer

    Author Photo

    Taekwondo has taught me to recognize when to fight for a position and when to focus on finding a solution, and that the best outcomes are often achieved by solving problems — all of which has improved my work as a bankruptcy lawyer, mediator and Subchapter V trustee, says Amy Denton Mayer at Berger Singerman.

  • Why AI Diligence Is Especially Key In IP Practice

    Author Photo

    In light of recent federal court sanctions against intellectual property litigators for filing work product generated by artificial intelligence without verification, it's important to consider the unique risks and consequences that can arise from overreliance on AI, which poses less visible risks in IP matters, says Stephen Ball at Husch Blackwell.

  • How 'Most Favored Nation' Regime Affects Biopharma Deals

    Author Photo

    As M&A activity surges in the biopharma space, companies will need to account for the Trump administration's most-favored-nation pricing proposals — durable in concept, if unsettled in detail — when drafting deals, say attorneys at Gibson Dunn.

  • What To Know As Legal Duty To Consider AI Takes Shape

    Author Photo

    While the U.K. Jurisdiction Taskforce’s recent statement on liability for artificial intelligence harms is nonbinding for both U.K. and U.S. lawyers, it highlights the importance of being able to distinguish between the availability of a tool and a professional obligation to use it, say Jonny Frank and Michael Costa at StoneTurn.

  • NC Dental Review Change Counters Tougher National Trend

    Author Photo

    North Carolina’s elimination of its prior review requirement for dental management agreements departs sharply from the national trend toward expanded corporate practice of medicine oversight, but stakeholders should not view this regulatory shift as a relaxation of compliance expectations, say attorneys at Holland & Knight.

  • NY Bill Would Boost Litigation Risk For Cosmetics Cos.

    Author Photo

    The Beauty Justice Act, now pending in the New York Legislature, would not only present compliance challenges for companies making cosmetics and personal care products, but could also be used by private plaintiffs to bring consumer fraud, false advertising, toxic exposure and product liability claims, says Kadeejah Kelly-Previl at Faegre Drinker.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.